BACKGROUND: Autosomal dominant optic atrophy (ADOA, Kjer disease, MIM #165500) is the most common form of hereditary optic neuropathy. Mutations in OPA1 located at chromosome 3q28 are the predominant cause for ADOA explaining between 32 and 89% of cases. Although deletions of OPA1 were recently reported in ADOA, the frequency of OPA1 genomic rearrangements in Denmark, where ADOA has a high prevalence, is unknown. The aim of the study was to identify copy number variations in OPA1 in Danish ADOA patients. METHODS: Forty unrelated ADOA patients, selected from a group of 100 ADOA patients as being negative for OPA1 point mutations, were tested for genomic rearrangements in OPA1 by multiplex ligation probe amplification (MLPA). When only one probe was abnormal results were confirmed by additional manually added probes. Segregation analysis was performed in families with detected mutations when possible. RESULTS: Ten families had OPA1 deletions, including two with deletions of the entire coding region and eight with intragenic deletions. Segregation analysis was possible in five families, and showed that the deletions segregated with the disease. CONCLUSION: Deletions in the OPA1 gene were found in 10 patients presenting with phenotypic autosomal dominant optic neuropathy. Genetic testing for deletions in OPA1 should be offered for patients with clinically diagnosed ADOA and no OPA1 mutations detected by DNA sequencing analysis.
BACKGROUND:Autosomal dominant optic atrophy (ADOA, Kjer disease, MIM #165500) is the most common form of hereditary optic neuropathy. Mutations in OPA1 located at chromosome 3q28 are the predominant cause for ADOA explaining between 32 and 89% of cases. Although deletions of OPA1 were recently reported in ADOA, the frequency of OPA1 genomic rearrangements in Denmark, where ADOA has a high prevalence, is unknown. The aim of the study was to identify copy number variations in OPA1 in Danish ADOA patients. METHODS: Forty unrelated ADOA patients, selected from a group of 100 ADOA patients as being negative for OPA1 point mutations, were tested for genomic rearrangements in OPA1 by multiplex ligation probe amplification (MLPA). When only one probe was abnormal results were confirmed by additional manually added probes. Segregation analysis was performed in families with detected mutations when possible. RESULTS: Ten families had OPA1 deletions, including two with deletions of the entire coding region and eight with intragenic deletions. Segregation analysis was possible in five families, and showed that the deletions segregated with the disease. CONCLUSION: Deletions in the OPA1 gene were found in 10 patients presenting with phenotypic autosomal dominant optic neuropathy. Genetic testing for deletions in OPA1 should be offered for patients with clinically diagnosed ADOA and no OPA1 mutations detected by DNA sequencing analysis.
Authors: F Barbet; S Hakiki; C Orssaud; S Gerber; I Perrault; S Hanein; D Ducroq; J-L Dufier; A Munnich; J Kaplan; J-M Rozet Journal: J Med Genet Date: 2005-01 Impact factor: 6.318
Authors: V Paracchini; M Seia; D Coviello; L Porcaro; L Costantino; P Capasso; D Degiorgio; R Padoan; C Corbetta; L Claut; D Costantini; C Colombo Journal: Clin Genet Date: 2008-02-13 Impact factor: 4.438
Authors: N Fuhrmann; M V Alavi; P Bitoun; S Woernle; G Auburger; B Leo-Kottler; P Yu-Wai-Man; P Chinnery; B Wissinger Journal: J Med Genet Date: 2009-02 Impact factor: 6.318
Authors: S Ellard; K Thomas; E L Edghill; M Owens; L Ambye; J Cropper; J Little; M Strachan; A Stride; B Ersoy; H Eiberg; O Pedersen; M H Shepherd; T Hansen; L W Harries; A T Hattersley Journal: Diabetologia Date: 2007-09-08 Impact factor: 10.122
Authors: Eric D Gaier; Katherine Boudreault; Isao Nakata; Maria Janessian; Philip Skidd; Elizabeth DelBono; Keri F Allen; Louis R Pasquale; Emily Place; Dean M Cestari; Rebecca C Stacy; Joseph F Rizzo; Janey L Wiggs Journal: Mol Vis Date: 2017-08-10 Impact factor: 2.367